Your browser doesn't support javascript.
loading
INSPIRE: A European training network to foster research and training in cardiovascular safety pharmacology.
Guns, Pieter-Jan D; Guth, Brian D; Braam, Stefan; Kosmidis, Georgios; Matsa, Elena; Delaunois, Annie; Gryshkova, Vitalina; Bernasconi, Sylvain; Knot, Harm J; Shemesh, Yair; Chen, Alon; Markert, Michael; Fernández, Miguel A; Lombardi, Damiano; Grandmont, Céline; Cillero-Pastor, Berta; Heeren, Ron M A; Martinet, Wim; Woolard, Jeanette; Skinner, Matt; Segers, Vincent F M; Franssen, Constantijn; Van Craenenbroeck, Emeline M; Volders, Paul G A; Pauwelyn, Thomas; Braeken, Dries; Yanez, Paz; Correll, Krystle; Yang, Xi; Prior, Helen; Kismihók, Gábor; De Meyer, Guido R Y; Valentin, Jean-Pierre.
Afiliação
  • Guns PD; Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium. Electronic address: pieter-jan.guns@uantwerpen.be.
  • Guth BD; Boehringer Ingelheim Pharma GmbH & Co KG, Drug Discovery Sciences, Biberach an der Riss, Germany.
  • Braam S; Ncardia B.V, Leiden, the Netherlands.
  • Kosmidis G; Ncardia B.V, Leiden, the Netherlands.
  • Matsa E; Ncardia B.V, Leiden, the Netherlands.
  • Delaunois A; UCB Biopharma SRL, Early Solutions, Development Science, Non-Clinical Safety Evaluation, Braine-l'Alleud, Belgium.
  • Gryshkova V; UCB Biopharma SRL, Early Solutions, Development Science, Non-Clinical Safety Evaluation, Braine-l'Alleud, Belgium.
  • Bernasconi S; NOTOCORD, an Instem company, Le Pecq, France.
  • Knot HJ; TSE Systems GmbH, Bad Homburg, Germany.
  • Shemesh Y; Department of Neurobiology, Weizmann Institute of Science, Rehovot, Israel.
  • Chen A; Department of Neurobiology, Weizmann Institute of Science, Rehovot, Israel.
  • Markert M; Boehringer Ingelheim Pharma GmbH & Co KG, Drug Discovery Sciences, Biberach an der Riss, Germany.
  • Fernández MA; Inria, Sorbonne Université & CNRS, Paris, France.
  • Lombardi D; Inria, Sorbonne Université & CNRS, Paris, France.
  • Grandmont C; Inria, Sorbonne Université & CNRS, Paris, France.
  • Cillero-Pastor B; The Maastricht MultiModal Molecular Imaging Institute (M4I), Division of Imaging Mass Spectrometry, Maastricht University, Maastricht, the Netherlands.
  • Heeren RMA; The Maastricht MultiModal Molecular Imaging Institute (M4I), Division of Imaging Mass Spectrometry, Maastricht University, Maastricht, the Netherlands.
  • Martinet W; Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium.
  • Woolard J; Division of Physiology, Pharmacology and Neuroscience, Centre of Membrane Proteins and Receptors (COMPARE), School of Life Sciences, University of Nottingham, United Kingdom.
  • Skinner M; Vivonics Preclinical Ltd, BioCity, Nottingham, United Kingdom.
  • Segers VFM; Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium; Department of Cardiology, Antwerp University Hospital, Antwerp, Belgium.
  • Franssen C; Department of Cardiology, Antwerp University Hospital, Antwerp, Belgium; Cardiovascular Diseases, GENCOR, University of Antwerp, Antwerp, Belgium.
  • Van Craenenbroeck EM; Department of Cardiology, Antwerp University Hospital, Antwerp, Belgium; Cardiovascular Diseases, GENCOR, University of Antwerp, Antwerp, Belgium.
  • Volders PGA; Department of Cardiology, CARIM, Maastricht University Medical Center+, Maastricht, the Netherlands.
  • Pauwelyn T; Life Science Technologies, imec, Leuven, Belgium.
  • Braeken D; Life Science Technologies, imec, Leuven, Belgium.
  • Yanez P; Department of Research Affairs & Innovation, University of Antwerp, Antwerp, Belgium.
  • Correll K; Safety Pharmacology Society, Reston, Virginia, United States.
  • Yang X; Division of Cardiovascular and Renal Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, United States.
  • Prior H; National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), London, UK.
  • Kismihók G; Leibniz Information Centre for Science and Technology, Hannover, Germany; Marie Curie Alumni Association, Brussels, Belgium.
  • De Meyer GRY; Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium.
  • Valentin JP; UCB Biopharma SRL, Early Solutions, Development Science, Non-Clinical Safety Evaluation, Braine-l'Alleud, Belgium.
J Pharmacol Toxicol Methods ; 105: 106889, 2020 Sep.
Article em En | MEDLINE | ID: mdl-32565326
Safety pharmacology is an essential part of drug development aiming to identify, evaluate and investigate undesirable pharmacodynamic properties of a drug primarily prior to clinical trials. In particular, cardiovascular adverse drug reactions (ADR) have halted many drug development programs. Safety pharmacology has successfully implemented a screening strategy to detect cardiovascular liabilities, but there is room for further refinement. In this setting, we present the INSPIRE project, a European Training Network in safety pharmacology for Early Stage Researchers (ESRs), funded by the European Commission's H2020-MSCA-ITN programme. INSPIRE has recruited 15 ESR fellows that will conduct an individual PhD-research project for a period of 36 months. INSPIRE aims to be complementary to ongoing research initiatives. With this as a goal, an inventory of collaborative research initiatives in safety pharmacology was created and the ESR projects have been designed to be complementary to this roadmap. Overall, INSPIRE aims to improve cardiovascular safety evaluation, either by investigating technological innovations or by adding mechanistic insight in emerging safety concerns, as observed in the field of cardio-oncology. Finally, in addition to its hands-on research pillar, INSPIRE will organize a number of summer schools and workshops that will be open to the wider community as well. In summary, INSPIRE aims to foster both research and training in safety pharmacology and hopes to inspire the future generation of safety scientists.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Farmacologia / Sistema Cardiovascular / Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / Desenvolvimento de Medicamentos Limite: Humans Idioma: En Revista: J Pharmacol Toxicol Methods Assunto da revista: FARMACOLOGIA / TOXICOLOGIA Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Farmacologia / Sistema Cardiovascular / Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / Desenvolvimento de Medicamentos Limite: Humans Idioma: En Revista: J Pharmacol Toxicol Methods Assunto da revista: FARMACOLOGIA / TOXICOLOGIA Ano de publicação: 2020 Tipo de documento: Article